Search results
Added:
1 month ago
Added:
3 months ago
Added:
8 months ago
Dive into our collection covering the hot line and late-breaking trials presented at EuroPCR 2025. Reviewing the sessions you don't want to miss, interventional experts Prof Nicolas Van MieghemandDr Joost Daemen will be leading our regular series View From the Thoraxcenter. For a deeper dive into the most anticipated trials, our Expert Interviews have you covered.
View more
Added:
2 months ago
Source:
Radcliffe Cardiology
New long-term data from the Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients (STEP) trial suggests that sustained, intensive blood pressure (BP) control provides greater cardiovascular benefits compared to a delayed approach in older patients with hypertension.¹ The findings also indicate that the earlier intensive treatment is initiated, the greater the reduction in…
View more
Added:
1 year ago
Source:
ESC Congress
The European Society of Cardiology has revealed 12 Hot-Line trial sessions to be presented at the end of August.ESC Congress 2024 will be held from the 30thAugust to the 2nd September at the ExCel Center in London. View the full programme here.Don't miss our video collection covering late-breaking data from ESC Congress 2024, including a preview of the most anticipated trials in View from the…
View more
Added:
4 months ago
Added:
2 years ago
AHA 2023 — Investigator, Dr A Michael Lincoff (Cleveland Clinic, US) sat down with Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) to discuss the SELECT trial (NCT03574597).In this randomized, double-blind, parallel-group, placebo-controlled trial sponsored by Novo Nordisk, semaglutide was compared with a placebo in patients who have overweight or obesity and a history of…
View more
Added:
1 year ago
ACC 2024 — Late-breaker host Dr Harriette Van Spall (McMaster University, CA) sits down with Dr James L. Januzzi (Massachusetts General Hospital & Harvard Medical School, US) to discuss the latest findings from the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure trial (ARISE-HF, Applied Therapeutics, Inc) (NCT04083339).This phase 3 multicenter, randomized,…
View more
Added:
2 years ago
HFA 23 - In this short interview, Prof Martin Cowie (Clinical Vice-President AstraZeneca R&D & Honorary Consultant Cardiologist, Guy’s & St Thomas’ NHS Foundation Trust, London, UK) joins us to discuss the findings from a prespecified analysis of the DELIVER trial which covered the characteristics, outcomes and effects of dapagliflozin according to the duration of heart failure.
DELIVER was…
View more
Added:
1 year ago
ACC.24 — Join Late-Breaker host, Dr Harriette Van Spall (McMaster University, CA), and Principal Investigator, Dr Javed Butler (University of Mississippi Medical Center, US), as they discuss the key findings from the EMPACT-MI trial (Boehringer Ingelheim)(NCT04509674).In this multicentre, randomised, parallel group, double-blind placebo-controlled superiority trial, investigators evaluated the…
View more